Keywords von Willebrand factor - von Willebrand disease - diabetes mellitus - endothelial dysfunction
- atherosclerosis - cardiovascular disease - swine
Introduction
von Willebrand factor (VWF), which is mainly produced in endothelial cells, is a prohemostatic
protein with an important role in hemostasis.[1 ]
[2 ] The primary function of VWF is to mediate platelet adhesion and aggregation.[1 ]
[2 ] VWF is also a carrier protein for factor VIII (FVIII), and thereby prevents FVIII
degradation. Consequently, plasma levels of VWF and FVIII are strongly correlated.[1 ]
[2 ]
It is known from large-population studies that high VWF levels are associated with
an increased risk of cardiovascular disease, such as acute myocardial infarction and
ischemic stroke, worse outcome of cardiovascular disease, and cardiovascular mortality.[3 ]
[4 ]
[5 ]
[6 ]
[7 ] VWF and FVIII levels have been shown to be influenced by genetic factors, age, blood
group, physical stress, and several other environmental factors.[8 ]
[9 ]
[10 ] For decades it was thought that aging directly leads to an increase in VWF and FVIII
levels.[8 ]
[9 ]
[11 ]
[12 ] However, recently we have shown that incidence of comorbidities such as diabetes
mellitus (DM), hypertension, cancer, and thyroid dysfunction at an older age may explain
the association between aging and increased VWF and FVIII levels.[10 ] Nevertheless, due to the cross-sectional design of that study, it could not be determined
whether there was a causal relation between comorbidities and the increase in VWF
and FVIII levels. Moreover, we could not investigate whether comorbidities directly
lead to an increase in VWF and FVIII levels, or whether this occurs secondary to endothelial
dysfunction or atherosclerosis. Indeed, previous studies found that VWF levels were
associated with carotid artery and aortic arch calcification, suggesting that increased
VWF levels may be the result of endothelial dysfunction or atherosclerosis.[5 ]
[6 ]
Since the association between VWF and cardiovascular disease and mortality is still
not fully understood, it is important to gain more insight into the pathophysiological
pathways linking cardiovascular risk factors with the increase in VWF and FVIII levels.[13 ]
[14 ]
[15 ] On one hand, increased VWF and FVIII levels may be strong, independent risk factors
for cardiovascular disease and mortality.[14 ]
[15 ] On the other hand, the association between increased VWF and FVIII levels and cardiovascular
disease and mortality may be partly confounded by comorbidities, such as DM and hypercholesterolemia
(HC), which are also well-established risk factors for cardiovascular disease and
mortality.[13 ] Moreover, it is still debated whether increased VWF and FVIII levels lead to endothelial
dysfunction and atherosclerosis or vice versa.[13 ] The large population studies on which most of our current knowledge about the association
between VWF and cardiovascular disease and mortality are based could not determine
the pathophysiological pathways underlying the association between VWF, endothelial
dysfunction, atherosclerosis, and cardiovascular disease and outcomes. Knowledge about
these pathways may contribute to a better understanding of previous studies and to
establish whether VWF is merely a biomarker for endothelial dysfunction and atherosclerosis
or whether it has a direct causative role, making it suitable as a drug target for
prevention or treatment of cardiovascular disease.[13 ]
To address these questions, we first investigated the pathophysiological pathways
of the comorbidity-related increase of VWF and FVIII levels in a randomized controlled
trial (RCT) design in swine with short-term (5 months) DM + HC, to study the direct
effects of these comorbidities on VWF and FVIII levels, at a time when endothelial
dysfunction and atherosclerosis were still absent. Subsequently, we studied VWF levels
in swine exposed to longer term (15 months) DM + HC at a time when endothelial dysfunction
and atherosclerosis were present.
Methods
We studied two cohorts of swine. In the first cohort Göttingen miniswine were subjected
to 5 months of DM + HC, while in the second cohort Landrace–Yorkshire farm swine were
subjected to 15 months of DM + HC or HC alone. All experiments were conducted in a
time period of 20 months, animals were ordered in groups of eight or nine animals,
and each group was evenly randomized to prevent selection bias and minimize the possibility
of time-dependent confounding. All experiments were performed in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals (eighth
edition, National Research Council, Washington, DC, The National Academies Press,
2011) and were approved by the Animal Care Committee at Erasmus Medical Center.
Short-Term Cohort
Induction of Metabolic Derangement in Swine
A total of 34 adult male Göttingen miniswine (Ellegaard Göttingen Miniswine A/S, Dalmose,
Denmark) were enrolled in the first part of the study. Swine were randomized into
an experimental group in which DM and HC were induced, and a control group which continued
on normal swine chow. DM was induced with intravenous injections of streptozotocin
(25 mg/kg/d), over 3 days (total dose: 75 mg/kg) as previously described.[16 ] One week later an isocaloric high-fat and high-sugar diet (25% of saturated fats,
1% of cholesterol, 10% sucrose, and 15% fructose) was gradually introduced in these
swine.[16 ] Swine were group-housed with a separate individual access to food for 1 hour/meal,
twice daily for the entire study duration, and ad libitum access to water. All swine
were followed up for 5 months, to study the short-term effect of DM + HC on VWF and
FVIII levels.
Of note, after 3 months of follow-up, both control and DM + HC groups were further
subdivided into a subgroup exposed to exercise training and a sedentary subgroup.
Since exercise training did not influence the results and conclusions of the current
study, we pooled the exercised and sedentary swine, and present the results for the
pooled DM + HC and pooled control group. The influence of exercise on VWF and FVIII
levels are presented in [Supplementary Table S1 ] (available in the online version).
Table 1
Characteristics of swine enrolled in the short-term RCT
DM + HC (n = 18)
Controls (n = 16)
p -Value[a ]
Age at inclusion (mo)
19.0 [16.5–19.0]
18.0 [15.5–19.0]
p = 0.699
Weight (kg)
Baseline
32.1 [25.9–36.1]
27.8 [25.3–37.3]
p = 0.931
3 mo
34.0 [30.6–43.8]
34.2 [30.4–39.1]
p = 0.783
5 mo
37.4 [29.1–42.9]
35.8 [34.1–39.5]
p = 0.904
Triglycerides (mmol/L)
Baseline
0.24 [0.21–0.31]
0.29 [0.24–0.37]
p = 0.087
3 mo
0.42 [0.26–1.34]
0.26 [0.25–0.34]
p = 0.031
5 mo
0.51 [0.27–1.14]
0.25 [0.21–0.30]
p = 0.001
Total cholesterol (mmol/L)
Baseline
0.90 [0.80–1.10]
0.90 [0.70–1.05]
p = 0.515
3 mo
5.35 [2.45–8.35]
1.15 [0.83–1.38]
p < 0.001
5 mo
5.10 [2.80–6.68]
1.15 [1.00–1.28]
p < 0.001
HDL cholesterol (mmol/L)
Baseline
0.58 [0.49–0.63]
0.54 [0.38–0.64]
p = 0.490
3 mo
2.71 [1.82–3.31]
0.72 [0.64–0.80]
p < 0.001
5 mo
2.61 [1.75–3.20]
0.68 [0.61–0.97]
p < 0.001
LDL cholesterol (mmol/L)
Baseline
0.38 [0.32–0.51]
0.40 [0.31–0.53]
p = 0.959
3 mo
2.60 [0.85–5.96]
0.41 [0.34–0.53]
p < 0.001
5 mo
2.50 [1.06–4.31]
0.41 [0.34–0.49]
p < 0.001
Glucose (mmol/L)
Baseline
4.8 [4.2–6.0]
5.7 [5.3–6.6]
p = 0.015
3 mo
11.5 [7.7–17.9]
5.7 [4.5–6.4]
p < 0.001
5 mo
15.7 [8.1–18.3]
6.3 [4.5–8.4]
p < 0.001
Abbreviations: DM, diabetes mellitus; HC, hypercholesterolemia; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; RCT, randomized controlled trial.
Note: Data are presented as median and interquartile range.
a Mann–Whitney U test between DM + HC and controls.
Plasma Metabolic, VWF, and FVIII Laboratory Measurements
Venous blood samples were obtained from lightly sedated animals by insertion of a
20 Gauge Venflon into an ear vein. Blood was collected in a heparin-coated collecting
tube at fasting state at baseline, 3-month, and 5-month (termination) time points,
and analyzed for glucose, triglyceride, and cholesterol using standardized human protocols
at the clinical chemical laboratory of the Erasmus Medical Center, Rotterdam. Venous
blood samples were also collected in collecting tubes containing 3.2% trisodium citrate,
centrifuged, and stored at −80°C for analyses of VWF and FVIII. VWF antigen (VWF:Ag)
was measured with an in‐house enzyme‐linked immunosorbent assay using polyclonal rabbit
anti‐human VWF antibodies (DakoCytomation, Glostrup, Denmark). It has previously been
shown that human VWF assays can be used to measure VWF in porcine plasma.[17 ] FVIII activity (FVIII:C) was measured using a one‐stage clotting assay on the Sysmex
CS-5100 (Siemens).
Hemodynamic Assessments, Coronary Angiography, and Cardiac Tissue Sampling and Analyses
After 5 months (at termination), animals were sedated with zoletil (Tiletamine/Zolazepam;
5 mg/kg intramuscular), rompun (xylazine; 2.25 mg/kg intramuscular), and atropine
(2 mL intramuscular), anesthetized with pentobarbital (20 mg/kg intravenous) and artificially
ventilated. Thereafter, a 9F sheath was placed in the left carotid artery and a standard
clinical guiding catheter (JL3.5, Boston Scientific) was advanced through the carotid
artery to the coronary ostium for angiography of the coronary arteries using iodixanol
as a contrast agent (Visipaque, GE Healthcare BV, Eindhoven, The Netherlands). Following
thoracotomy, hearts were arrested, immediately excised, and quickly washed in cold
saline solution and then the apex was placed in ice-cold, oxygenated Krebs bicarbonate
buffer solution. Subsequently, epicardial small coronary arteries (∼300 µm diameter)
were isolated of both groups for functional experiments. The large coronary arteries
were fixed in 4% buffered formaldehyde, embedded in paraffin, and stained with resorcin-fuchsin
to assess atherosclerosis development in both groups.
Microvascular Function In Vitro
The isolated segments were studied in vitro in a Mulvany wire myograph (DMT, Aarhus,
Denmark) as previously described.[18 ] In short, after a 30-minute stabilization period, vessels were normalized to 90%
of the estimated diameter at 100 mmHg effective transmural pressure. Thereafter, the
vascular segments were depolarized by 100 mM KCl (Sigma-Aldrich, Zwijndrecht, The
Netherlands) to determine the maximal contractile response of the small-artery segments.
Subsequently, vasodilator or vasoconstrictor responses to various substances (all
bought from Sigma-Aldrich) were acquired using separate, but in vivo adjacently positioned,
segments. Endothelium-dependent vasodilation was studied by measurement of vasodilation
in response to bradykinin (BK 10−8 M) following preconstriction by the thromboxane A2 analog U46619 (10−6 M). Endothelium-independent vasodilation was studied in separate small-artery segments
by measuring the vasodilatory response to the exogenous NO-donor S-nitroso-N-acetyl-D,
L-penicillamine (SNAP 10−7 M). In additional small-artery segments, vasoconstriction to endothelin-1 (ET-1 10−8 M) was measured. Previous research studies from our group and others have demonstrated
a group size of five to eight swine to be sufficient to detect biological relevant
differences in coronary microvascular function (80% confidence, two-tailed test, α
= 0.05).[18 ]
[19 ]
[20 ]
[21 ]
[22 ]
[23 ]
Long-Term Longitudinal Cohort
The longitudinal cohort was described in detail previously.[18 ] Briefly, 10 Landrace–Yorkshire swine were included in the study at 3 months of age.
In five swine DM was induced with a single intravenous injection of streptozotocin
(140–180 mg/kg). In the DM swine and the remaining five swine without DM, HC was induced
with a high-fat and high-sugar diet, as described above. Food intake was monitored
for each animal separately and titrated to maintain growth at approximately 1.5 kg/week.
After 9, 12, and 15 months of exposure to HC or DM + HC, arterial citrate plasma samples
were collected to measure VWF:Ag, and coronary angiograms were recorded, as described
above. After 15 months of induction of DM + HC, animals were terminated and microvascular
function and large coronary atherosclerosis development were determined, as described
above. Additionally, 12 fresh slaughterhouse swine hearts were collected as controls
to assess small coronary artery function.
Statistical Analysis
Continuous data are presented as median and interquartile range (IQR; in square brackets),
whereas categorical data are presented as frequency and proportion (in first parentheses).
Normality of data was visually assessed with histograms. Because VWF:Ag and FVIII:C
were not normally distributed, nonparametric tests were used. The Mann–Whitney U test
was used to analyze a difference between two independent groups, whereas the Kruskal–Wallis
test was used to analyze a difference between three groups. A difference between two
related groups was analyzed with the Wilcoxon signed-rank test.
The correlation between VWF and FVIII was assessed with Spearman's correlation analysis.
Outcomes of this analysis are presented as Spearman's rho (ρ) and p -value. The association between the FVIII:C/VWF:Ag ratio and cholesterol levels was
calculated with linear regression analysis, since the FVIII:C/VWF:Ag ratio was normally
distributed. Outcomes of linear regression analysis are presented as unstandardized
β and p -value.
A p -value below 0.05 was defined as statistically significant. Analyses were performed
with SPSS Statistics Version 25.0 (IBM Corp. Armonk, New York, United States).
Results
Short-Term Cohort
Thirty-four adult male Göttingen miniswine were included in our RCT, of which 18 swine
were randomized to the experimental group (DM + HC) and 16 swine to the control group.
At baseline no difference was observed in age (respectively 19.0 months [16.5–19.0]
vs. 18.0 months [15.5–19.0], p = 0.699; values in median [IQR]), body weight (31.1 kg [25.9–36.1] vs. 27.8 kg [
25.3–37.3], p = 0.931), or in metabolic parameters between DM + HC swine and control swine ([Table 1 ]). As expected, DM + HC swine demonstrated robust hyperglycemia and dyslipidemia
with triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, total cholesterol, and glucose all two- to fivefold higher in DM + HC
swine compared with control swine at 3 and 5 months ([Table 1 ]). However, 5 months of exposure to hyperglycemia and dyslipidemia did not result
in coronary atherosclerosis, as evidenced by the absence of atherosclerosis on the
coronary angiograms and histologic preparations of coronary arteries in DM + HC and
control swine ([Fig. 1 ]).
Fig. 1 No signs of atherosclerosis of coronary arteries in both DM + HC and control swine
after 5 months of follow-up. No signs of coronary atherosclerosis were observed in
both groups. Typical examples of (A ) coronary angiograms at a left anterior oblique 30° and a cranial 0° view and (B ) resorcin-fuchsin stained large coronary arteries of controls and DM + HC. DM, diabetes
mellitus; HC, hypercholesterolemia; VWF, von Willebrand factor.
Microvascular Function
In the coronary small arteries, endothelium-dependent vasodilation to BK was similar
in DM + HC swine compared with controls at 5 months (p = 0.497, [Table 2 ]). Endothelium-independent vasodilation was also similar, as the response to NO-donor
SNAP was also not different between groups (p = 0.217). Vasoconstriction to ET-1 resulted also in similar responses in both groups
(p = 0.739). Taken together, these data show the absence of endothelial dysfunction
in the coronary circulation in swine up to 5 months after induction of DM + HC.
Table 2
No difference in coronary endothelial function between DM + HC swine and controls
in the short-term RCT
DM + HC (n = 14)
Control (n = 13)
p -Value[a ]
Bradykinin[b ]
71.9% [49.9–90.1]
53.3% [40.6–87.2]
p = 0.497
SNAP[b ]
34.1% [11.4–60.4]
51.4% [28.5–69.1]
p = 0.217
ET-1[c ]
55.1% [31.5–78.6]
41.1% [14.2–100.0]
p = 0.739
Abbreviations: DM, diabetes mellitus; ET-1, endothelin-1; HC, hypercholesterolemia;
RCT, randomized controlled trial; SNAP, S-nitroso-N-acetyl-D, L-penicillamine.
Note: Data are presented as median and interquartile range.
a Mann–Whitney U test between DM + HC and controls.
b % Vasodilation.
c % Vasoconstriction.
VWF:Ag and FVIII:C during 5 Months of Follow-Up
VWF:Ag was not different between DM + HC and control swine at baseline (0.44 IU/mL
[0.38–0.50] vs. 0.40 IU/mL [0.36–0.45], p = 0.171). Also no difference was observed at 3 months (0.31 IU/mL [0.29–0.33] vs.
0.33 IU/mL [0.26–0.35], p = 0.191) or 5 months (0.34 IU/mL [0.28–0.39] vs. 0.34 [0.31–0.38], p = 0.644) of follow-up ([Fig. 2A ]). Furthermore, no increase of VWF:Ag was observed between baseline and 5-month follow-up
in either group ([Fig. 2A ]).
Fig. 2 VWF antigen did not increase during 5 months of follow-up (A ), whereas FVIII activity did increase (B ). Data presented as mean and 95% confidence interval. *p < 0.05 between DM + HC and controls. †
p < 0.05 compared with baseline levels in DM + HC swine. DM, diabetes mellitus; FVIII,
factor VIII; HC, hypercholesterolemia; VWF, von Willebrand factor.
FVIII:C remained unchanged over time in controls, whereas it steadily increased in
DM + HC swine, reaching statistical significance at 5 month follow-up compared with
baseline levels (p = 0.026, [Fig. 2B ]). As a result, FVIII:C was significantly higher in DM + HC swine compared with control
swine at 5-month follow-up (respectively 5.85 IU/mL [5.00–6.81] vs. 4.57 IU/mL [3.76–5.40],
p = 0.010; [Fig. 2B ]).
Correlation between VWF:Ag and FVIII:C
At baseline, a strong correlation was observed between VWF:Ag and FVIII:C ([Fig. 3A ]), which was statistically significant in DM + HC swine (r = 0.63, p = 0.006). At 3-month follow-up this correlation slightly decreased in DM + HC swine
(r = 0.55, p = 0.027, [Fig. 3B ]), and at 5 months this correlation disappeared in DM + HC swine (r = 0.18, p = 0.513), whereas it was strongly present in controls (r = 0.84, p < 0.001, [Fig. 3C ]). This was due to the fact that DM + HC swine had relatively higher FVIII:C compared
with VWF:Ag at 5-month follow-up ([Fig. 3C ]).
Fig. 3 The correlation between VWF and FVIII disappeared in DM + HC swine during 5 months
of follow-up. (A ) At baseline, the correlation between VWF:Ag and FVIII:C was r = 0.63 (p = 0.006) in DM + HC swine and r = 0.44 (p = 0.116) in controls. (B ) At 3 months of follow-up, this correlation was r = 0.55 (p = 0.027) in DM + HC swine and r = 52 (0.058) in controls. (C ) At 5 months, this correlation disappeared in DM + HC swine (r = 0.18, p = 0.513), whereas it was strongly present in controls (r = 0.84, p < 0.001). Outcomes of Spearman's correlation analysis are provided. Ag, antigen;
DM diabetes mellitus; FVIII, factor VIII; HC hypercholesterolemia; VWF, von Willebrand
factor.
Cholesterol levels were positively associated with the FVIII:C/VWF:Ag ratio at 3 and
5 months of follow-up ([Fig. 4 ]). The linear association between cholesterol and the FVIII:C/VWF:Ag ratio was β = 1.2 (p = 0.490) at baseline, β = 0.6 (p = 0.022) at 3 months, and β = 0.9 (p = 0.002) at 5 months. Similar associations were found between LDL, HDL, triglycerides,
and FVIII:C/VWF:Ag ratio ([Supplementary Fig. S1 ], available in the online version). Cholesterol was not significantly associated
with FVIII:C alone at baseline, 3 months, and 5 months ([Supplementary Fig. S2 ], available in the online version). Furthermore, higher glucose at 5 months was also
associated with higher FVIII:C (β = 0.08, p = 0.043), but not with VWF:Ag (β = 0.00, p = 0.120, [Supplementary Fig. S3 ], available in the online version). Together these results indicate that increased
plasma levels of cholesterol and glucose result in higher FVIII:C without change of
VWF:Ag.
Fig. 4 Higher cholesterol was associated with a higher FVIII/VWF ratio. (A ) At baseline, there was no correlation between total cholesterol and FVIII:C/VWF:Ag
ratio. (B ) At 3 months total cholesterol was correlated with FVIII:C/VWF:Ag, and (C ) at 5 months this correlation was even stronger. Outcomes of linear regression analysis
are provided. Ag, antigen; DM diabetes mellitus; FVIII, factor VIII; HC hypercholesterolemia;
VWF, von Willebrand factor.
Long-Term Longitudinal Cohort
In the long-term longitudinal cohort, VWF:Ag was first measured 9 months after induction
of HC and DM + HC. At that time, both groups had robust dyslipidemia as evidenced
by—comparable to the short-term cohort—high levels of cholesterol and triglycerides,
whereas fasting hyperglycemia was only present in DM + HC swine ([Table 3 ]). Plasma lipid and glucose levels of these swine remained constant between 9 and
15 months of follow-up ([Table 3 ]).
Table 3
Characteristics of swine in the long-term longitudinal cohort
HC (n = 5)
DM + HC (n = 5)
Triglycerides (mmol/L)
9 mo
0.37 [0.16–1.33]
0.87 [0.39–1.63]
12 mo
0.32 [0.23–0.62]
0.41 [0.30–1.41]
15 mo
0.42 [0.32–1.08]
0.64 [0.38–2.46]
Total cholesterol (mmol/L)
9 mo
18.0 [14.1–27.1]
16.1 [15.2–26.1]
12 mo
18.6 [13.8–25.8]
18.2 [12.6–21.9]
15 mo
19.0 [12.0–23.8]
17.9 [12.9–20.3]
HDL cholesterol (mmol/L)
9 mo
5.87 [5.44–6.50]
5.02 [4.47–6.01]
12 mo
6.10 [5.21–6.57]
5.99 [4.48–6.52]
15 mo
5.72 [5.04–6.36]
5.30 [4.33–5.82]
LDL cholesterol (mmol/L)
9 mo
15.3 [11.6–21.9]
12.3 [11.5–22.4]
12 mo
14.9 [11.3–22.2]
15.0 [9.4–17.2]
15 mo
15.2 [9.4–20.2]
14.0 [9.8–17.3]
Glucose (mmol/L)
9 mo
3.7 [3.4–4.8]
11.1 [9.1–24.4]
12 mo
4.0 [3.8–4.4]
9.4 [8.5–20.9]
15 mo
4.8 [4.5–5.9]
15.8 [9.0–27.3]
Abbreviations: DM, diabetes mellitus; HC, hypercholesterolemia; HDL, high-density
lipoprotein; LDL, low-density lipoprotein.
Note: Data are presented as median and interquartile range.
In contrast to the short-term cohort, coronary angiograms showed that from 9 months
on, atherosclerosis progressively developed in large coronary arteries of both HC
and DM + HC swine ([Fig. 5A ]). Histological studies at 15 months also showed clear atherosclerosis in large coronary
arteries of both HC and DM + HC swine ([Fig. 5B ]). Likewise, at 15 months both HC and DM + HC swine had endothelial dysfunction as
evidenced by significantly increased vasoconstrictor responses to ET-1 ([Table 4 ]), which was, at least partly, due to a loss of endothelium-dependent endothelin
receptor B-mediated dilation as discussed before.[18 ]
Table 4
Endothelial dysfunction in coronaries of HC and DM + HC in the long term cohort
HC (n = 4)
DM + HC (n = 5)
Controls (n = 6–18[a ])
p -Value[b ]
Bradykinin[c ]
82.3% [74.6–87.9]
89.2% [78.6–90.7]
77.0% [62.7–88.4]
p = 0.400
SNAP[c ]
57.2% [48.8–63.2]
40.7% [33.6–66.0]
24.8% [17.8–48.9]
p = 0.321
ET-1[d ]
63.4% [58.2–80.9]
58.8% [46.5–82.9]
19.7% [9.1–28.4]
p = 0.003
Abbreviations: DM, diabetes mellitus; ET-1, endothelin 1; HC, hypercholesterolemia;
SNAP, S-nitroso-N-acetyl-D, L-penicillamine.
Note: Data are presented as median and interquartile range.
a Controls: bradykinin n = 6, SNAP n = 18, ET-1 n = 11.
b Kruskal–Wallis test between all three groups.
c % Vasodilation.
d % Vasoconstriction.
Fig. 5 There were clear signs of atherosclerosis present in large coronary arteries of both
HC and DM + HC swine after 15 months of follow-up in the long-term longitudinal cohort.
(A ) Examples of progressive, from 9 (9 M), 12 (12 M), and 15 (15 M) months, coronary
lesions on coronary angiograms at a left anterior oblique 30° and a cranial 0° view
of both HC and DM + HC swine. (B ) Typical examples resorcin-fuchsin stained large coronary arteries of atherosclerosis
of HC and DM + HC swine at 15 months (15 M) of the long-term longitudinal cohort.
DM diabetes mellitus; HC hypercholesterolemia.
Increase of VWF:Ag during 15 Months of Follow-Up
In line with the progressive development of atherosclerosis, VWF levels gradually
increased over time in HC and DM + HC swine ([Fig. 6 ]). In HC swine, VWF:Ag was 0.27 IU/mL [0.23–0.40] at 9 months, 0.34 IU/mL [0.28–0.36]
at 12 months, and 0.37 IU/mL [0.32–0.42] at 15 months ([Fig. 6 ]). Thus, VWF:Ag was significantly higher at 15 months compared with 9 months (p = 0.042) and 12 months (p = 0.043, [Fig. 6 ]). In DM + HC swine, VWF:Ag was 0.25 IU/mL [0.24–0.33] at 9 months and significantly
increased to 0.30 IU/mL [0.28–0.35] (p = 0.042) at 12 months and 0.33 IU/mL [0.32–0.37] (p = 0.042) at 15 months ([Fig. 6 ]).
Fig. 6 VWF levels progressively increased in HC and DM + HC swine in the long-term longitudinal
cohort. Data presented as mean and 95% confidence interval. *p < 0.05 compared with baseline levels in both groups. †
p < 0.05 compared with levels at 12 months in HC swine. #
p < 0.05 compared with baseline levels in DM + HC swine. DM diabetes mellitus; HC hypercholesterolemia;
VWF, von Willebrand factor.
Discussion
In the present study in swine exposed to cardiovascular risk factors, we found that
FVIII levels, but not VWF levels, increased after 5 months of exposure to DM and HC.
This increase in FVIII levels was independent of VWF levels, which remained stable
over time, and was associated with plasma cholesterol, LDL, HDL, triglycerides, and
glucose levels. Five months of exposure to HC and DM did not lead to endothelial dysfunction
or atherosclerosis. However, long-term (15 months) exposure to DM and HC did result
in increased VWF levels, at a time when endothelial dysfunction and atherosclerosis
were present.
These results suggest that endothelial dysfunction and atherosclerosis are the major
determinants of the increase in VWF levels over time in swine with DM and HC. Similarly,
a study in mice found that DM and hyperglycemia eventually led to increased VWF levels
via endothelial dysfunction.[24 ] Our findings may explain the results of previous studies in humans showing an association
between high VWF levels and extensive atherosclerosis, cardiovascular disease, and
worse cardiovascular outcomes.[5 ]
[6 ] Since atherosclerosis and endothelial dysfunction lead to both higher VWF levels
and worse cardiovascular outcomes, VWF may be seen as a biomarker for advanced cardiovascular
disease. In line with this, two large population-based cohort studies concluded that
VWF is primarily a biomarker of cardiovascular disease, instead of a strong causal
factor.[25 ]
[26 ] However, VWF may, by its procoagulant function promoting platelet aggregation and
thrombosis, also have an additional direct effect on cardiovascular outcomes.[14 ]
[27 ] Therefore, well-designed studies are needed to investigate the contribution of each
of these two mechanisms (i.e., indirect role of VWF as biomarker vs. direct procoagulant
role of VWF) in the relation between VWF and cardiovascular disease and outcomes.
Such information may provide more insights into how effective potential VWF-targeted
treatment for prevention or treatment of cardiovascular disease may be.
Endothelial dysfunction and atherosclerosis may lead to higher VWF levels due to increased
VWF release from dysfunctional endothelial cells.[28 ] However, atherosclerosis development may also attenuate VWF clearance by macrophages.
It is known that macrophages play a critical role in VWF clearance, by binding and
clearing VWF in a dose-dependent manner.[29 ]
[30 ] At the same time, macrophages play a key role in development of atherosclerosis.[31 ] Internalization of LDL particles by macrophages and formation of foam cells can
be accompanied by macrophage apoptosis.[31 ] Therefore, it is very likely that changes in macrophages during the development
of atherosclerosis may contribute to the increase of VWF levels over time. In line
with this, it has been shown that diet-induced obesity leads to higher VWF and FVIII
levels in mice via both increased synthesis and reduced clearance of VWF.[32 ]
Interestingly, FVIII levels increased shortly after induction of HC and hyperglycemia,
whereas VWF levels remained unchanged, resulting in the disappearance of the correlation
between VWF and FVIII levels in DM + HC swine after 5 months of follow-up. In line
with this, a recent large study in the general population of 5,778 individuals found
that higher fasting glucose was associated with higher FVIII levels, even after adjustment
for confounders, whereas a RCT in 12 healthy volunteers found that hyperglycemia did
not affect VWF levels during a short-term follow-up period.[33 ]
[34 ] On the long term, it has also been shown that patients with DM have higher VWF and
FVIII levels than healthy individuals in the general population, possibly due to long-term
consequences of DM.[35 ]
[36 ]
[37 ] However, in contrast, the Biobreeding Wistar rat, which is a model of spontaneous
autoimmune type 1 DM, showed similar VWF levels compared with controls during a long-term
follow-up period.[38 ] There are several possible mechanisms by which hyperglycemia may increase FVIII
levels. Hyperglycemia may lead to loss of endothelial glycocalyx and subsequently
activation of the coagulation system, resulting in a direct increase of FVIII levels.[39 ] Additionally, increased oxidative stress during hyperglycemia may lead to higher
FVIII levels.[33 ] Furthermore, FVIII levels may be directly increased due to HC, as the region within
the C2 domain of FVIII involved in VWF binding can also bind lipids.[40 ] Therefore, in severe HC, FVIII may (besides VWF) bind lipids, thereby prolonging
the half-life of FVIII, independent of VWF. In line with this, we found that a higher
FVIII/VWF ratio was associated with higher levels of total cholesterol, LDL, HDL,
and triglycerides. Also, it has previously been shown in mice that FVIII–lipid binding,
besides VWF–FVIII binding, synergistically prolongs the plasma survival of FVIII.[41 ] During normal conditions the role of VWF–FVIII binding on FVIII survival is larger,
because of the high binding affinity of VWF with FVIII (0.5 nM).[42 ]
[43 ] However, in a high lipid environment, lipids may, despite a lower binding affinity
to FVIII (6 nM, compared with VWF), contribute significantly to FVIII survival by
additional lipid–FVIII binding.[41 ]
[42 ] In line with this, we have found that cholesterol is associated with the FVIII:C/VWF:Ag
ratio stronger than that with the FVIII:C ratio alone.
The current study may also have important implications for patients with von Willebrand
disease (VWD), which is caused by reduced VWF levels, leading to bleeding symptoms.[44 ]
[45 ]
[46 ]
[47 ] Our results suggest that endothelial dysfunction and atherosclerosis mediate comorbidity-dependent
increase in VWF levels in patients with type 1 VWD.[10 ] Similarly, our data are in accordance with human data showing that body mass index,
which is highly related to endothelial dysfunction and atherosclerosis, was associated
with higher VWF and FVIII levels in type 1 VWD patients.[48 ] Altogether, these data suggest that not only the incidence of comorbidities, but
also the severity of endothelial dysfunction and atherosclerosis modulates VWF and
FVIII levels.[12 ]
[31 ]
[48 ]
[49 ] Prospective studies in VWD patients are needed to investigate the effect of the
comorbidity-related increase of VWF and FVIII levels on the bleeding tendency of these
patients.[50 ]
To our knowledge, this is the first study to investigate the pathophysiological mechanisms
of the increase of VWF and FVIII levels in a relevant large animal model with cardiovascular
risk factors using a RCT design. For this study, we employed swine, which have proven
to be an excellent model for human metabolic syndrome and cardiovascular disease,
mainly due to their similarities to humans with regards to their glucose and lipid
metabolism, cardiovascular anatomy, physiology, and myocardial metabolism.[51 ]
[52 ]
[53 ] Swine also show great resemblance to humans with regards to both VWF and VWD.[54 ] In this study, we showed that hyperglycemia and HC increase FVIII levels, independent
of VWF. In addition, we showed that VWF levels only increased when endothelial dysfunction
and atherosclerosis were present. Nevertheless, this study has several potential limitations.
First, the most important limitation is that we did not measure baseline VWF levels
in the long-term longitudinal cohort study, as no citrated blood was collected at
inclusion in the study. Notwithstanding this limitation, we found that VWF levels
progressively increased in HC and DM + HC swine with overt endothelial dysfunction
and atherosclerosis during the period between 9- and 15- months of follow-up. Second,
there was no control group in the long-term cohort study. Finally, we did not measure
FVIII levels in the long-term longitudinal cohort, as citrate plasma was not available
anymore to measure FVIII levels. However, we clearly show in the short-term RCT cohort
that FVIII levels increased because of hyperglycemia and HC, independent of VWF.
In conclusion, the present study shows that endothelial dysfunction and atherosclerosis
lead to an increase of VWF levels in swine, whereas hyperglycemia and HC already increased
FVIII levels prior to development of endothelial dysfunction and atherosclerosis ([Fig. 7 ]). Therefore, VWF seems to be a biomarker for advanced cardiovascular disease. These
findings contribute to a better understanding of the association between high VWF
and FVIII levels and atherosclerosis, cardiovascular disease, and a worse cardiovascular
outcome in humans.
Fig. 7 Summary of the association between comorbidities, endothelial dysfunction, and atherosclerosis
and VWF and FVIII levels. Aging gives a higher chance for comorbidities, which leads
to an increase of FVIII via HC and hyperglycemia, but does not influence VWF. Over
a long time period, comorbidities lead to endothelial dysfunction and atherosclerosis,
which increase VWF. Because of the strong physiologic association between VWF and
FVIII, an increase of VWF will subsequently also lead to higher FVIII levels. DM diabetes
mellitus; FVIII, factor VIII; HC hypercholesterolemia; VWF, von Willebrand factor.
What is known about this topic?
VWF and FVIII levels are associated with an increased risk of cardiovascular disease.
VWF and FVIII levels increase with aging, possibly due to incidence of comorbidities
at an older age.
What does this paper add?
VWF increase over time is mediated via endothelial dysfunction and atherosclerosis,
whereas short-term hyperglycemia and dyslipidemia increase FVIII.
VWF seems to be a biomarker for advanced cardiovascular disease, explaining its association
with cardiovascular disease and outcomes.
